Logo image of FLGT

FULGENT GENETICS INC (FLGT) Stock Fundamental Analysis

NASDAQ:FLGT - US3596641098 - Common Stock

22.17 USD
+0.14 (+0.64%)
Last: 8/29/2025, 8:22:38 PM
22.17 USD
0 (0%)
After Hours: 8/29/2025, 8:22:38 PM
Fundamental Rating

4

Taking everything into account, FLGT scores 4 out of 10 in our fundamental rating. FLGT was compared to 102 industry peers in the Health Care Providers & Services industry. The financial health of FLGT is average, but there are quite some concerns on its profitability. While showing a medium growth rate, FLGT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year FLGT was profitable.
FLGT had a negative operating cash flow in the past year.
In multiple years FLGT reported negative net income over the last 5 years.
In the past 5 years FLGT always reported a positive cash flow from operatings.
FLGT Yearly Net Income VS EBIT VS OCF VS FCFFLGT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

The Return On Assets of FLGT (-4.25%) is worse than 62.75% of its industry peers.
FLGT has a Return On Equity of -4.57%. This is comparable to the rest of the industry: FLGT outperforms 46.08% of its industry peers.
Industry RankSector Rank
ROA -4.25%
ROE -4.57%
ROIC N/A
ROA(3y)-2.25%
ROA(5y)12.71%
ROE(3y)-2.41%
ROE(5y)14.84%
ROIC(3y)N/A
ROIC(5y)N/A
FLGT Yearly ROA, ROE, ROICFLGT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

With a decent Gross Margin value of 40.04%, FLGT is doing good in the industry, outperforming 69.61% of the companies in the same industry.
FLGT's Gross Margin has declined in the last couple of years.
FLGT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 40.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.53%
GM growth 5Y-7.75%
FLGT Yearly Profit, Operating, Gross MarginsFLGT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

6

2. Health

2.1 Basic Checks

FLGT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FLGT has been increased compared to 1 year ago.
Compared to 5 years ago, FLGT has more shares outstanding
FLGT has a better debt/assets ratio than last year.
FLGT Yearly Shares OutstandingFLGT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
FLGT Yearly Total Debt VS Total AssetsFLGT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 5.95 indicates that FLGT is not in any danger for bankruptcy at the moment.
The Altman-Z score of FLGT (5.95) is better than 86.27% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that FLGT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, FLGT belongs to the top of the industry, outperforming 87.25% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.95
ROIC/WACCN/A
WACC8.87%
FLGT Yearly LT Debt VS Equity VS FCFFLGT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

FLGT has a Current Ratio of 6.01. This indicates that FLGT is financially healthy and has no problem in meeting its short term obligations.
FLGT's Current ratio of 6.01 is amongst the best of the industry. FLGT outperforms 94.12% of its industry peers.
A Quick Ratio of 6.01 indicates that FLGT has no problem at all paying its short term obligations.
FLGT's Quick ratio of 6.01 is amongst the best of the industry. FLGT outperforms 94.12% of its industry peers.
Industry RankSector Rank
Current Ratio 6.01
Quick Ratio 6.01
FLGT Yearly Current Assets VS Current LiabilitesFLGT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

FLGT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1433.33%, which is quite impressive.
FLGT shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.18% yearly.
The Revenue has been growing slightly by 4.30% in the past year.
FLGT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 54.21% yearly.
EPS 1Y (TTM)1433.33%
EPS 3Y-68.94%
EPS 5Y22.18%
EPS Q2Q%-53.33%
Revenue 1Y (TTM)4.3%
Revenue growth 3Y-34.15%
Revenue growth 5Y54.21%
Sales Q2Q%15.17%

3.2 Future

Based on estimates for the next years, FLGT will show a very negative growth in Earnings Per Share. The EPS will decrease by -40.44% on average per year.
The Revenue is expected to grow by 11.14% on average over the next years. This is quite good.
EPS Next Y-192.98%
EPS Next 2Y-83.3%
EPS Next 3Y-40.44%
EPS Next 5YN/A
Revenue Next Year12.97%
Revenue Next 2Y11.77%
Revenue Next 3Y11.14%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
FLGT Yearly Revenue VS EstimatesFLGT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
FLGT Yearly EPS VS EstimatesFLGT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 48.20, which means the current valuation is very expensive for FLGT.
FLGT's Price/Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Earnings ratio of 27.13, FLGT is valued quite expensively.
The Forward Price/Earnings Ratio is negative for FLGT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 48.2
Fwd PE N/A
FLGT Price Earnings VS Forward Price EarningsFLGT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FLGT Per share dataFLGT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

A cheap valuation may be justified as FLGT's earnings are expected to decrease with -40.44% in the coming years.
PEG (NY)N/A
PEG (5Y)2.17
EPS Next 2Y-83.3%
EPS Next 3Y-40.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FLGT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FULGENT GENETICS INC

NASDAQ:FLGT (8/29/2025, 8:22:38 PM)

After market: 22.17 0 (0%)

22.17

+0.14 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-01 2025-08-01/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners54.79%
Inst Owner Change-0.07%
Ins Owners33.39%
Ins Owner Change1.4%
Market Cap678.62M
Analysts77.78
Price Target25.84 (16.55%)
Short Float %10.32%
Short Ratio7.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)129.32%
Min EPS beat(2)121.2%
Max EPS beat(2)137.43%
EPS beat(4)4
Avg EPS beat(4)172.16%
Min EPS beat(4)121.2%
Max EPS beat(4)298.21%
EPS beat(8)7
Avg EPS beat(8)139.31%
EPS beat(12)11
Avg EPS beat(12)145.2%
EPS beat(16)15
Avg EPS beat(16)113.81%
Revenue beat(2)2
Avg Revenue beat(2)3.16%
Min Revenue beat(2)1.07%
Max Revenue beat(2)5.24%
Revenue beat(4)2
Avg Revenue beat(4)0.65%
Min Revenue beat(4)-1.93%
Max Revenue beat(4)5.24%
Revenue beat(8)5
Avg Revenue beat(8)4.41%
Revenue beat(12)9
Avg Revenue beat(12)6.22%
Revenue beat(16)12
Avg Revenue beat(16)6.53%
PT rev (1m)11.76%
PT rev (3m)11.76%
EPS NQ rev (1m)-13.56%
EPS NQ rev (3m)-1216.65%
EPS NY rev (1m)18.79%
EPS NY rev (3m)20.71%
Revenue NQ rev (1m)3.77%
Revenue NQ rev (3m)-3.56%
Revenue NY rev (1m)3.04%
Revenue NY rev (3m)3.04%
Valuation
Industry RankSector Rank
PE 48.2
Fwd PE N/A
P/S 2.24
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 0.7
EV/EBITDA N/A
EPS(TTM)0.46
EY2.07%
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-1.96
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS9.91
BVpS36.48
TBVpS31.48
PEG (NY)N/A
PEG (5Y)2.17
Profitability
Industry RankSector Rank
ROA -4.25%
ROE -4.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 40.04%
FCFM N/A
ROA(3y)-2.25%
ROA(5y)12.71%
ROE(3y)-2.41%
ROE(5y)14.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.53%
GM growth 5Y-7.75%
F-Score6
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 144.73%
Cap/Sales 11.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.01
Quick Ratio 6.01
Altman-Z 5.95
F-Score6
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)101.39%
Cap/Depr(5y)338.11%
Cap/Sales(3y)8.31%
Cap/Sales(5y)7.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1433.33%
EPS 3Y-68.94%
EPS 5Y22.18%
EPS Q2Q%-53.33%
EPS Next Y-192.98%
EPS Next 2Y-83.3%
EPS Next 3Y-40.44%
EPS Next 5YN/A
Revenue 1Y (TTM)4.3%
Revenue growth 3Y-34.15%
Revenue growth 5Y54.21%
Sales Q2Q%15.17%
Revenue Next Year12.97%
Revenue Next 2Y11.77%
Revenue Next 3Y11.14%
Revenue Next 5YN/A
EBIT growth 1Y-1.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.56%
EBIT Next 3Y25.57%
EBIT Next 5YN/A
FCF growth 1Y-290.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-144.97%
OCF growth 3Y-66.06%
OCF growth 5Y30.8%